How will the introduction of HBV NAT reduce the residual risk of transfusion-transmitted HBV infection?
Introduction of HBV NAT will reduce the residual risk of transfusion-transmitted HBV infection by: • Improving the detection of acute HBV infection • As HBV DNA is the first detectable marker in acute HBV infection (ie, before HBsAg), introduction of HBV NAT will reduce the infectious window period (see diagram below).
